TO THE EDITOR
We read with interest the paper by Madan et al 1 reporting a patient with Waldenstrom's macroglobulinemia (WM) that terminated in acute lymphoblastic leukemia (ALL). The authors postulated that the two diseases arose from the same clone and that the WM had evolved into the ALL. We would like to present our experience with a patient with multiple myeloma (MM) who developed ALL 3 years after tandem autologous stem cell transplantations (ASCT).
A 60-year-old woman presented with low back pain in June 2000. Initial investigations revealed anemia and multiple lumbar compression fractures. Serum immunoelectrophoresis showed increased monoclonal IgG and k light chain. The bone marrow (BM) was infiltrated by malignant plasma cells (50% of nucleated cells) with blastic appearance (Figure 1a) , and conventional G-banding cytogenetics revealed a complex karyotype (Table 1) . A diagnosis of stage IIIA MM was made, and the patient was commenced on the VAD (vincristine, doxorubicin, dexamethasone) regimen.
After four cycles of VAD, although the M band was still detectable, IgG and k light-chain levels had normalized. We mobilized and collected her peripheral blood stem cells (total CD34 cells: 8.1 Â 10 6 /kg) using cyclophosphamide (4 g/m 2 ) and G-CSF. A repeat BM examination just before the first ASCT in December 2000 revealed both morphologic and cytogenetic remissions. She underwent tandem ASCT 6 months apart, each time with high-dose melphalan (140 mg/m 2 ) as the conditioning regimen. She made rapid recovery after each ASCT without much complication. Repeat investigations in August 2001 confirmed morphologic and cytogenetic remissions with normal levels of immunoglobulins and absence of the M band.
Thereafter, the patient remained well but in November 2003 she developed symptoms of anemia. A complete blood count (CBC) showed white blood cell count, 6.88 Â 10 9 /l, hemoglobin, 8.1 g/dl and platelet count, 76 Â 10 9 /l, with 35% of blast cells. The BM was heavily infiltrated by blasts (up to 90%), immunophenotyped as lymphoblasts (Figure 1b 
, CyIgMÀ, CykÀ, CylÀ, CD45À, CD138À, CD56À, myeloid and T-cell antigens negative. G-banding cytogenetics revealed new chromosomal abnormalities ( Table 1 ), suggesting that the ALL might have arisen from a clone different from the original MM. Specific reverse transcription-polymerase chain reaction (RT-PCR) for detection of the t(9;22)(q34;q11) translocation was negative. Thus, a diagnosis of ALL, of pre-pre-B immunophenotype, was made.
In view of the poor overall prognosis of this condition, the patient was managed conservatively with steroids alone. This resulted in normalization of the CBC with no detectable peripheral blasts for 6 months. In June 2004, leukopenia recurred. A repeat BM examination showed 50% lymphoblasts and further cytogenetic evolution ( Table 1 ). The patient has since been restarted on another course of steroids.
We performed IgH gene rearrangement studies on genomic DNA extracted from both the BM aspirates at the time of diagnosis of MM and ALL. PCR amplification was performed using primers homologous to a conserved VH framework III region and the J region of the gene. The amplified PCR products were detected by capillary gel electrophoresis on the ABI Prism 310 Genetic Analyser (Applied Biosystems Inc., Foster City, CA, USA). This revealed a dominant peak at the region of 107 bp in the first sample and one at the region of 122 bp in the second sample (Figure 2 ), confirming that two separate monoclonal Bcell populations were involved in the pathogenesis of these two lymphoid malignancies at the two different time points.
To our knowledge, this is the first reported case of MM terminating in ALL. It prompts discussion of whether MM can evolve or transform into ALL, much like Richter's transformation of low-grade lymphoid malignancy. 2 MM is a malignancy of the postgerminal center, somatically mutated, isotype-switched, long-lived BM plasma cells. 3 Theoretically, for lymphoblastic leukemic transformation to take place, de-or retrodifferentiation of mature plasma cells to immature pre-pre-B cells should occur. There is currently little evidence that this phenomenon can happen either in vivo or in vitro. Moreover, both cytogenetic and IgH gene rearrangement studies demonstrated an absence of genetic relatedness between the two diseases, strongly suggesting that they were two separate clonal lymphoid disorders. 2 Hence, in our opinion, this is most likely a therapy-related ALL (t-ALL) genetically unrelated to the original MM. Therapy-related myelodysplastic syndromes (t-MDS) and acute myeloid leukemias (t-AMLs) due to chemotherapy, radiotherapy as well as stem cell transplantation are well described in the literature. [4] [5] [6] In patients with MM, the actuarial risk of developing t-AML has been shown to be 3-5% at 3 years and 10-15% after 10 years of alkylating agent therapy. 6 There is also evidence suggesting that prolonged alkylating agent therapy prior to transplantation, rather than ASCT-related myeloablative treatment, is associated with the development of t-MDS and t-AML.
7 t-ALLs are, on the other hand, rare. Most cases were accompanied by 11q23 abnormalities and none had been reported in the setting of MM. 8, 9 Our patient developed ALL after exposure to relatively low cumulative doses of both alkylating agents and anthracyclinecyclophosphamide, 4 g/m 2 , melphalan, 280 mg/m 2 and doxorubicin, 108 mg/m 2 -during her treatment period. There were no 11q23 abnormalities. In fact, the cytogenetic abnormalities, which included chromosome 7 abnormalities, trisomy 8 and del(20q), were more consistent with therapy-related myeloid malignancies. We were also unable to discern any morphologic features of MDS on the BM aspirates.
From this case study, we were able to make the following observations. Firstly, even low cumulative doses of chemotherapeutic agents, perhaps, acting in concert with the inherent genetic and epigenetic instability of malignant myeloma cells, Secondly, 'myeloid-type' chromosomal abnormalities do not necessarily always lead to eventual myeloid malignancies. These chromosomal changes could have occurred in a lymphoid progenitor cell, culminating in the eventual development of ALL. Thirdly, t-ALL can occur as a terminal event in MM, two genetically unrelated clonal disorders.
In conclusion, we describe a patient with MM who developed ALL after a short course of standard chemotherapy and tandem ASCT. Further investigations showed that the two lymphoid disorders were separate clonal diseases. We postulate that the underlying pathogenesis is likely an interaction between the chemotherapy and the inherent genetic instability of either or both the normal or abnormal lymphoid cells.
LG Lau (1) 48,XX,der(7)del(7)(?p12)del(7)(q31),+8, add(9)(p22),+14,del(20)(q11) 21 (2) The gradual accumulation of malignant cells in B-CLL is probably due to disturbances in the balance between programmed cell death and cell proliferation. It has been recently suggested that inhibitory CTLA-4 (cytotoxic T lymphocyteassociated antigen 4; CD152) molecule may be involved in the cell cycle machinery; 1,2 however, the role of CTLA-4 in cell cycle progression is relatively well understood in T cells only. CTLA-4 seems to prolong the progression through the G1 phase of the cell cycle by upregulation of cyclin D2 and inhibition of cyclin D3, cdk4, and cdk6 production.
1,2 CTLA-4 also affects the degradation of cyclin-dependent kinase inhibitor p27
KIP1
and contributes to its earlier and stronger re-expression during the late stages of T-cell activation.
1,2 As little is known about CTLA-4 expression/function in normal and neoplastic B cells, we have extended our previous study concerning G1 cell cycle phase regulators in B-CLL cells 3 in the context of their association with the expression of CTLA-4.
We estimated both the surface and intracellular expression of CTLA-4 molecule in peripheral blood CD19 þ /CD5 þ lymphocytes derived from B-CLL patients in relation to the stage of the disease and the cell cycle phase distribution of these lymphocytes. We also investigated the associations between CTLA-4 expression and the levels of cyclin D2, cyclin D3, and p27 KIP1 in these cells. Based on the fact that CTLA-4 gene polymorphisms were reported to affect CTLA-4 protein level, 4 the relationships between the levels of CTLA-4 expression in leukemic cells and CTLA-4 gene polymorphisms in B-CLL patients were also examined.
A total of 39 B-CLL patients (in stages 0-IV according to the Rai classification) and 21 age-and sex-matched healthy controls entered the study. The criteria for diagnosis and disease progression have been previously described. 5 Direct surface and intracellular immunofluorescence staining were performed for the evaluation of the expressions of all studied proteins and the distribution of cell cycle phases. Cells were then analyzed by flow cytometry using a FACScalibur. Data were processed by CellQuest Software. Total genomic DNA was isolated from whole frozen blood. Both SNPs (A49G, C-318T) were identified using ABI PRISM SNaPshot ddNTP Primer Extension Reaction Kit and detected using the ABI PRISM s 310 capillary electrophoresis system. The STR polymorphism at locus 642 was studied by PCR and a fluorescence-based technique using a fluorescently labeled primer and GENESCANt-350ROXt STANDARD as an internal lane standard for an ABI PRISM s 310 capillary electrophoresis system. To compare independent variables, the Mann-Whitney U test was used. Spearman's rank measured the correlation between marker expression, Rai stages or cell cycle phase distribution. Statistical calculations were performed using the Statistica 5.1 program.
The present study showed for the first time a significantly higher mean proportion of CD19 þ /CD5 þ cells expressing CTLA-4 molecule both on the cell surface (sCTLA-4) and intracellularly (cCTLA-4) in all B-CLL patients compared with the control group (P ¼ 0.001 and Po0.000001) ( Table 1 ). In B-CLL patients, both sCTLA-4 and cCTLA-4 expression relative to the single cell, as measured semiquantitatively by estimating the mean fluorescence intensity of CTLA-4 (MFI), was also markedly elevated within the subset of CD19 þ /CD5 þ cells compared with the normal population (P ¼ 0.009 and P ¼ 0.000005, respectively) (Table 1) . Furthermore, we found positive correlation between sCTLA-4 as well as cCTLA-4 expression in leukemic cells and Rai stage (r s ¼ 0.62; P ¼ 0.003 and r s ¼ 0.43; P ¼ 0.05, respectively) (Figure 1a and b) .
To explain the great variation in CTLA-4 expression in leukemic cells, the B-CLL patients were stratified by genotype at the promoter (designated as C ). Furthermore, based on the number of (AT) repeats starting from position 642 in exon 4, we subdivided the patients into three groups with respect to the presence or absence of the 82 base-pair (bp) allele. The genotype distribution among B-CLL patients is shown in Table 2 . The patients categorized into groups according to these genotypes were then compared with regard to CTLA-4 expression. As for CTLA-4 gene dimorphisms at the promoter or exon 1, the differences in CTLA-4 expression, evaluated either as a proportion of triple-positive cells or MFI values, between genotype-related groups of patients were not statistically significant (Table 2) . However, we observed that the intracellular distribution of CTLA-4 was markedly higher in B-CLL patients carrying allele with 82 (AT) repeats than the longer allele of 82 bp in exon 4 (MFI values: 25.9711.9 vs 19.579.1, P ¼ 0.02). In addition, we analyzed the effect of combined
